DE60023493D1 - Verwendung von synthetischen FXR Liganden zur Behandlung von Krankheiten die mit einem gestörten Gleichgewicht des Cholesterin-Spiegels verbunden sind und von Kolonkrebs - Google Patents
Verwendung von synthetischen FXR Liganden zur Behandlung von Krankheiten die mit einem gestörten Gleichgewicht des Cholesterin-Spiegels verbunden sind und von KolonkrebsInfo
- Publication number
- DE60023493D1 DE60023493D1 DE60023493T DE60023493T DE60023493D1 DE 60023493 D1 DE60023493 D1 DE 60023493D1 DE 60023493 T DE60023493 T DE 60023493T DE 60023493 T DE60023493 T DE 60023493T DE 60023493 D1 DE60023493 D1 DE 60023493D1
- Authority
- DE
- Germany
- Prior art keywords
- colon cancer
- diseases associated
- cholesterol level
- treat diseases
- level balance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000029742 colonic neoplasm Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001771 impaired effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000260 hypercholesteremic effect Effects 0.000 abstract 1
- 230000000871 hypocholesterolemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13896899P | 1999-06-11 | 1999-06-11 | |
| US138968P | 1999-06-11 | ||
| PCT/US2000/015912 WO2000076523A1 (en) | 1999-06-11 | 2000-06-09 | Methods for modulating fxr receptor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60023493D1 true DE60023493D1 (de) | 2005-12-01 |
| DE60023493T2 DE60023493T2 (de) | 2006-07-20 |
Family
ID=22484498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60023493T Expired - Fee Related DE60023493T2 (de) | 1999-06-11 | 2000-06-09 | Verwendung von synthetischen FXR Liganden zur Behandlung von Krankheiten die mit einem gestörten Gleichgewicht des Cholesterin-Spiegels verbunden sind und von Kolonkrebs |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1185277B1 (de) |
| JP (1) | JP2003501477A (de) |
| CN (1) | CN1368884A (de) |
| AT (1) | ATE307595T1 (de) |
| AU (1) | AU768806B2 (de) |
| BR (1) | BR0011743A (de) |
| CA (1) | CA2377320A1 (de) |
| DE (1) | DE60023493T2 (de) |
| HK (1) | HK1047705A1 (de) |
| WO (1) | WO2000076523A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132223A1 (en) * | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| US20020119958A1 (en) * | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
| JP4021327B2 (ja) | 2001-03-12 | 2007-12-12 | インターセプト ファーマスーティカル インコーポレイテッド | Ｆｘｒに対する作用薬としてのステロイド |
| US20030144360A1 (en) * | 2001-11-19 | 2003-07-31 | Allergan Sales, Inc. | Composition and method for modulating BAR/FXR receptor activity |
| EP1465882B1 (de) | 2001-12-21 | 2011-08-24 | X-Ceptor Therapeutics, Inc. | Heterocyclische modulatoren von nukleären rezeptoren |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| US20050143449A1 (en) * | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| HUE032928T2 (hu) | 2004-03-12 | 2017-11-28 | Intercept Pharmaceuticals Inc | Fibrózis kezelése FXR-ligandumok alkalmazásával |
| US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| EA017714B1 (ru) | 2007-01-19 | 2013-02-28 | Интерсепт Фармасьютикалз, Инк. | Модуляторы tgr5 и способы их применения |
| EP2324046B1 (de) | 2008-07-30 | 2014-09-03 | Intercept Pharmaceuticals, Inc. | Tgr5-modulatoren und anwendungsverfahren dafür |
| JP5535233B2 (ja) | 2008-11-19 | 2014-07-02 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｔｇｒ５モジュレーターおよびその使用方法 |
| WO2010069604A1 (en) | 2008-12-19 | 2010-06-24 | Royal College Of Surgeons In Ireland | Treatment of diarrhoea |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| CN111228278A (zh) | 2012-06-19 | 2020-06-05 | 英特塞普特医药品公司 | 奥贝胆酸的制备、用途和固体形式 |
| PL3043865T3 (pl) | 2013-09-11 | 2021-07-05 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B |
| EP3600293A1 (de) | 2017-03-30 | 2020-02-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Verfahren und pharmazeutische zusammensetzungen zur reduzierung und expression von episomalen viren |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| CN114945361A (zh) | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Fxr激动剂在治疗丁型肝炎病毒感染中的用途 |
| US20240100125A1 (en) | 2021-01-14 | 2024-03-28 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| EP4329761A1 (de) | 2021-04-28 | 2024-03-06 | ENYO Pharma | Starke potenzierung von tlr3-agonisten-effekten mit fxr-agonisten als kombinierte behandlung |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588715A (en) * | 1984-06-04 | 1986-05-13 | Sandoz, Inc. | Heptenoic acid derivatives |
| FR2707989B1 (fr) * | 1993-07-22 | 1995-10-13 | Pf Medicament | Nouveaux dérivés de benzylamines silylées, leurs sels, leurs procédés de fabrication et les compositions pharmaceutiques les renfermant. |
-
2000
- 2000-06-09 DE DE60023493T patent/DE60023493T2/de not_active Expired - Fee Related
- 2000-06-09 WO PCT/US2000/015912 patent/WO2000076523A1/en not_active Ceased
- 2000-06-09 AT AT00941312T patent/ATE307595T1/de not_active IP Right Cessation
- 2000-06-09 AU AU56032/00A patent/AU768806B2/en not_active Ceased
- 2000-06-09 EP EP00941312A patent/EP1185277B1/de not_active Expired - Lifetime
- 2000-06-09 HK HK02109359.4A patent/HK1047705A1/zh unknown
- 2000-06-09 BR BR0011743-9A patent/BR0011743A/pt not_active IP Right Cessation
- 2000-06-09 JP JP2001502856A patent/JP2003501477A/ja active Pending
- 2000-06-09 CA CA002377320A patent/CA2377320A1/en not_active Abandoned
- 2000-06-09 CN CN00811519A patent/CN1368884A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000076523A1 (en) | 2000-12-21 |
| CA2377320A1 (en) | 2000-12-21 |
| BR0011743A (pt) | 2002-03-05 |
| JP2003501477A (ja) | 2003-01-14 |
| AU768806B2 (en) | 2004-01-08 |
| ATE307595T1 (de) | 2005-11-15 |
| AU5603200A (en) | 2001-01-02 |
| HK1047705A1 (zh) | 2003-03-07 |
| CN1368884A (zh) | 2002-09-11 |
| EP1185277B1 (de) | 2005-10-26 |
| EP1185277A1 (de) | 2002-03-13 |
| DE60023493T2 (de) | 2006-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60023493D1 (de) | Verwendung von synthetischen FXR Liganden zur Behandlung von Krankheiten die mit einem gestörten Gleichgewicht des Cholesterin-Spiegels verbunden sind und von Kolonkrebs | |
| DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
| ATE200863T1 (de) | Indolinonverbindungen zur behandlung von krankheiten | |
| DE60033030D1 (de) | Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit | |
| DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
| DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| AU2002345497A1 (en) | Cips as modifiers of the p53 pathway and method of use | |
| DE3683318D1 (de) | Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege. | |
| ATE298230T1 (de) | Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress | |
| ATE539795T1 (de) | Stimulation tiefer gehirnbereiche | |
| ATE297036T1 (de) | Verfahren und vorrichtung zum vorhersagen von menschlichen kognitiven leistung | |
| DE69637587D1 (de) | Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen | |
| DE69632743D1 (de) | Verfahren zur regulierung des vagaltonus | |
| BR9607894A (pt) | Processo para tratar tumores | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| EP0758894A4 (de) | Verwendung von alpha-1c spezifischen verbindungen zur behandlung der benignen prostatahyperplasie | |
| ATE158414T1 (de) | Neue gabaa-rezeptorsubtypen und verfahren zum screening von arzneimittelverbindungen unter verwendung von gabaa-rezeptorsubtypen bindende imidazochinoxaline und pyrrolopyrimidine | |
| TR199902192T2 (xx) | Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri | |
| DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| WO2003043581A3 (en) | Composition and method for modulating bar/fxr receptor activity | |
| NO981454D0 (no) | Anti-FAS-antistoffer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |